---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-024190"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:27:21.523405+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics enters separation agreement with ex-President Boris Minev; $287,500 in payments

## Summary
- Dr. Boris Minev ceased as President, Medical & Scientific Affairs and Section 16 officer effective July 29, 2025.
- Separation agreement provides $100,000 negotiated bonus for NNV1 and SNV1 IND approvals and $187,500 severance over 6 months.
- Company will pay COBRA premiums for 6 months.
- Agreement includes standard release of claims and non-disparagement; effective after 7-day revocation period.

## SEC filing metadata
- accession: 0001641172-25-024190
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000164117225024190/0001641172-25-024190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000164117225024190/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-024190
- JSON: https://secwatch.observer/filing/0001641172-25-024190.json
- Plain text: https://secwatch.observer/filing/0001641172-25-024190.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.